Press releases

Feb 15, 2024

   Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 13, 2024

   Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Dec 04, 2023

   SUNSHINE BIOPHARMA MOVES PRINCIPAL OFFICE TO NEW YORK CITY

Nov 13, 2023

   SUNSHINE BIOPHARMA REPORTS 2023 THIRD QUARTER RESULTS: REVENUES UP SIGNIFICANTLY OVER LAST YEAR DUE TO A KEY ACQUISITION

Sep 21, 2023

   SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION TO ACHIEVE NASDAQ MINIMUM BID COMPLIANCE

Aug 11, 2023

   SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600%

May 16, 2023

   SUNSHINE BIOPHARMA ANNOUNCES CLOSING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

May 12, 2023

   SUNSHINE BIOPHARMA ANNOUNCES PRICING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT THE MARKET

May 11, 2023

   SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%

Apr 05, 2023

   SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 28, 2023

   SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT

Feb 10, 2023

   SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND

Jan 19, 2023

   SUNSHINE BIOPHARMA ANNOUNCES SHARE REPURCHASE PROGRAM

Dec 20, 2022

   SUNSHINE BIOPHARMA’S ANNUAL LETTER TO SHAREHOLDERS

Nov 16, 2022

   SUNSHINE BIOPHARMA ENTERS INTO COLLABORATION WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT

Oct 20, 2022

   SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE

Jul 28, 2022

   SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA

Apr 28, 2022

   Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 26, 2022

   Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 25, 2022

   Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules…

Apr 05, 2022

   Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Mar 14, 2022

   Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

Mar 10, 2022

   Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market

Feb 25, 2022

   SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA

Feb 15, 2022

   Sunshine Biopharma Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

Dec 22, 2021

   Sunshine Biopharma Announces $1,361,000 in Debt Reduction

Nov 03, 2021

   SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS

Oct 06, 2021

   Sunshine Biopharma Files a Patent Application Covering mRNA Molecules…

Aug 12, 2021

   SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN

Jul 27, 2021

   Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement

Jul 20, 2021

   SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL

Jul 08, 2021

   Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer

Jun 09, 2021

   SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED

May 20, 2021

   SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

May 13, 2021

   SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING

May 04, 2021

   SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

Apr 23, 2021

   SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT

Apr 22, 2021

   RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA

Mar 23, 2021

   SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT

Mar 11, 2021

   SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033

Mar 04, 2021

   Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a And Initiates QA/QC Testing

Mar 01, 2021

   Sunshine Biopharma Launches Online Store for Its Science-Based Nutritional Supplements

Feb 18, 2021

   Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast

Feb 10, 2021

   SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY

Feb 04, 2021

   SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS

Feb 02, 2021

   SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033

Jan 27, 2021

   SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB

Jan 14, 2021

   SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Dec 22, 2020

   SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK

Dec 08, 2020

   SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS

Dec 03, 2020

   SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET

Dec 01, 2020

   SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 plus FINANCING FOR CORONAVIRUS TREATMENT

Nov 24, 2020

   SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY

Nov 18, 2020

   Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound

Nov 10, 2020

   Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East

Oct 26, 2020

   SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Oct 19, 2020

   SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG

Oct 07, 2020

   SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND

Sep 15, 2020

   SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Aug 25, 2020

   SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE

Jun 03, 2020

   SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT

Nov 06, 2019

   SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT

Oct 17, 2019

   SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER<

Sep 03, 2019

   Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement

May 28, 2019

   In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca

May 16, 2019

   Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com

Mar 12, 2019

   SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA

Feb 04, 2019

   Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033

Dec 17, 2018

   Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company’s First Over The Counter Essential Micronutrient

Dec 12, 2018

   Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug

Sep 14, 2018

   Sunshine Biopharma Announces $10 Million Equity Financing

Aug 16, 2018

   Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.

Jun 18, 2018

   Sunshine Biopharma Launches Microbiology Testing Service

May 10, 2018

   Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing

Jan 04, 2018

   Sunshine Biopharma Completes the Acquisition of Atlas Pharma

Sep 05, 2017

   Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million…

Jun 26, 2017

   Sunshine Biopharma Releases Results of Independent Valuation

Jun 19, 2017

   Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License

Jan 11, 2017

   Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing

Dec 09, 2016

   Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma

Jun 30, 2016

   Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH

May 11, 2016

   Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company’s First Generic Drug For Treatment Of Breast Cancer

Mar 15, 2016

   Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound

Dec 28, 2015

   Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound

Oct 09, 2015

   Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a

Aug 04, 2015

   Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a…

May 26, 2015

   Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland

Mar 24, 2015

   Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India

Feb 25, 2015

   Sunshine Biopharma Announces Change To Its Board Of Directors And Officers

Jan 20, 2015

   Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound

Nov 19, 2014

   Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a

Nov 03, 2014

   Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a

Oct 14, 2014

   Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations

Oct 01, 2014

   Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License

Sep 03, 2014

   Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound

Aug 21, 2014

   Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical…

Aug 11, 2014

   Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations

Jun 09, 2014

   Sunshine Biopharma’s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells

May 12, 2014

   Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada

Apr 29, 2014

   Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II

Apr 07, 2014

   Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro

Mar 31, 2014

   Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise

Feb 14, 2014

   Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a…

Jun 19, 2013

   Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling

Jun 04, 2013

   Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells

May 01, 2013

   Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers

Apr 09, 2013

   Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations

Mar 14, 2013

   Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant…

Feb 26, 2013

   Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a

Jan 15, 2013

   Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a…

Dec 10, 2012

   Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells

Dec 04, 2012

   Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a

Nov 27, 2012

   Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents

Nov 13, 2012

   Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a

Oct 09, 2012

   Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a

Sep 25, 2012

   Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in Oct. Issue of ANTICANCER RESEARCH

Sep 20, 2012

   Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials

Sep 13, 2012

   Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a

Sep 04, 2012

   Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of…

Aug 15, 2012

   Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal

Aug 03, 2012

   BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report

Jul 30, 2012

   Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

Jul 24, 2012

   Biotech Investor Alert: CFO of Sunshine Biopharma Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a

Jul 19, 2012

   Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)

Jul 11, 2012

   Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a

Jul 02, 2012

   Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound – Adva-27a for Aggressive Forms of Cancer

Jun 26, 2012

   Sunshine Biopharma’s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells

May 22, 2012

   Pharmacokinetics Parameters of Sunshine Biopharma’s Lead Anti-Cancer Compound Exceed Expectations

Apr 09, 2012

   Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound

Mar 26, 2012

   Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago

Nov 28, 2011

   Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals

Nov 15, 2011

   Sunshine Biopharma’s Announces Successful Completion of Preclinical Studies for Adva-27a, The Company’s Lead Anti-Cancer Compound

Oct 05, 2011

   Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor

Aug 30, 2011

   Clearance of Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate

Jul 27, 2011

   Sunshine Biopharma Looking to Mimic Roche’s Billion Dollar Cancer Drug Success

Jul 25, 2011

   Sunshine Biopharma’s Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism

Jul 11, 2011

   Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells

Jun 17, 2011

   Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada

Apr 01, 2011

   Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com

Mar 27, 2011

   Sunshine Biopharma’s Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays

Mar 04, 2011

   CEO CFO Interviews Dr. Steve N. Slilaty

Feb 25, 2011

   Interview with Central NY Business Journal

Jan 26, 2011

   FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1

Jan 21, 2011

   Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement

Oct 26, 2010

   CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.

Oct 13, 2010

   Sunshine Biopharma, Inc. Begins Drug Development Activities

Oct 20, 2009

   Mountain West Business Solutions Acquires Sunshine Biopharma